Therapeutic modulation of low-density lipoprotein size
Related Experiment Video
Updated: Aug 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
1Lipid Laboratory, Cape Heart Centre and MRC Cape Heart Group, University of Cape Town Health Sciences Faculty, Anzio Road, Observatory 7925, South Africa. dmarais@uctgsh1.uct.ac.za
Abstract:
Small, dense LDL particles have been linked to atherosclerosis, often in a cluster of risk factors and affecting approximately 20% of adults. Over the past year, studies confirmed that small dense LDL is an autosomal dominant trait, influenced mainly by hypertriglyceridaemia and obesity, insulin resistance and diabetes mellitus and some incompletely investigated genetic loci. Compositional and functional differences have been observed in small LDL. Evidence is emerging that lifestyle as well as pharmacological intervention can modulate LDL size, but there is no proof yet that this is of clinical benefit.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Bioavailability Enhancement: Drug Permeability Enhancement
Dosage Regimen: Individualization
Therapeutic Drug Monitoring: Affecting Factors
Modified-Release Drug Delivery Systems: Influencing Factors
Site-Targeted Drug Delivery Systems: Polymeric Carriers

